A Review on the Relationship between SGLT2 Inhibitors and Cancer

Table 3

Incidence rates of bladder and breast cancer with canagliflozin exposure.

Canagliflozin		Subjects with events (%)	Rate per 1000 patient-year
Bladder Cancer
Canagliflozin 100 mg	3139	2 (0.06)	0.44
Canagliflozin 300 mg	3506	3 (0.09)	0.63
All canagliflozin	6645	5 (0.07)
All noncanagliflozin	3640	4 (0.11)	0.84
Breast Cancer
Canagliflozin 100 mg	1313	5 (0.38)	2.61
Canagliflozin 300 mg	1514	7 (0.46)	3.39
All canagliflozin	2827	12 (0.42)
All noncanagliflozin	1501	6 (0.4)	3.05

Source: reference [14], data obtained from 8 phase 3 clinical trials, data cutoff date: Nov 15, 2012.